Christopoulos, P. ., , Bozorgmehr, F. ., Elsayed, M. ., Kirchner, M. ., Ristau, J. ., … Thomas, M. . (2018). EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> NSCLC. International Journal of Cancer. https://doi.org/10.1002/ijc.31275 (Original work published 2018)
